somatotroph comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
=== Sulfide analysis === The formation of methylene blue after the reaction of hydrogen sulfide with dimethyl-p-phenylenediamine and iron(III) at pH 0.4 – 0.7 is used to determine by photometric measurements sulfide concentration in the range 0.020 to 1.50 mg/L (20 ppb to 1.5 ppm). The test is very sensitive and the blue coloration developing upon contact of the reagents with dissolved H2S is stable for 60 min. Ready-to-use kits such as the Spectroquant sulfide test facilitate routine analyses. The methylene blue sulfide test is a convenient method often used in soil microbiology to quickly detect in water the metabolic activity of sulfate reducing bacteria (SRB). In this colorimetric test, methylene blue is a product formed by the reaction and not a reagent added to the system. The addition of a strong reducing agent, such as ascorbic acid, to a sulfide-containing solution is sometimes used to prevent sulfide oxidation from atmospheric oxygen. Although it is certainly a sound precaution for the determination of sulfide with an ion selective electrode, it might however hamper the development of the blue color if the freshly formed methylene blue is also reduced, as described here above in the paragraph on redox indicator.
=== Recursive directional ligation (RDL) === In recursive directional ligation, the gene encoding the monomer is inserted into a plasmid with restriction sites that are recognized by at least two endonucleases. The endonucleases will cut the plasmid, releasing the gene of interest. Then, this single gene is inserted into a recipient plasmid vector already containing one copy of the ELP monomer gene via digestion of the recipient plasmid with the same restriction endonucleases used on the donor plasmid and a subsequent ligation step. From this process, a sequence of two ELP monomer genes is retrieved. RDL allows for the controlled synthesis of ELP gene oligomers, in which single gene segments are sequentially added. However, the restriction endonucleases used are limited to those that do not cut within the ELP monomer gene itself, as this would lead to loss of crucial nucleotides and a potential frameshift mutation in the protein.
=== Structural convergence === Here is a list of examples in which unrelated proteins have similar tertiary structures but different functions. Whole protein structural convergence is not thought to occur but some convergence of pockets and secondary structural elements have been documented.
Greer (born 1945), American chemist notable for work on thermodynamics of fluids, polymer solutions and phase transitions François Auguste Victor Grignard (1871–1935), French chemist, 1912 Nobel Prize in Chemistry for his work on reactions important in the formation of carbon–carbon bonds Robert H. Grubbs (1942–2021), 2005 Nobel Prize in Chemistry for work on olefin metathesis Louis-Bernard Guyton de Morveau (1737–1816), French chemist known for establishing modern chemical nomenclature
Sources: en.wikipedia.org
Advanced Simulation Library Droplet-based microfluidics Fluidics Induced-charge electrokinetics Integrated fluidic circuit Lab-on-a-chip Microfluidic cell culture Microfluidic modulation spectroscopy Microphysiometry Micropumps Microvalves uFluids@Home Paper-based microfluidics
=== YxxCxxxF motif and GTS loop === The YxxCxxxF motif and GTS loop are two amino acid sites that are located in Domain 1 of eRF1. The YxxCxxxF motif is found in the amino acid residues 121-131, whereas the GTS loop is found in amnio acid residues 31-33. The YxxCxxxF is composed of three invariant amino acid residues: Tyrosine (Y), Cysteine (C), and Phenylalanine (F). These sites are structurally separated in the folded eRF1 protein, however their main functions are very similar. They are responsible for purine recognition in position 2 and 3 of the stop codon.
=== Masculinity and social bonds === Comics scholar Jeffrey K. Johnson argues that Wolverine incarnates cultural values of the Reagan era, emphasizing individualism and retributive justice. Similarly, Neil Shyminsky claims that "Wolverine's appeal is grounded in nostalgia for a morally absolute brand of dangerous masculinity." Gerri Mahn, however, draws attention to the theme of vulnerability in Wolverine's stories, particularly the Fatal Attractions story in which Wolverine is gravely injured by Magneto and loses his adamantium bone lacing. Mahn claims that this experience of recuperation from injury presented an opportunity for Wolverine to redefine his gender identity, establishing more caring bonds with others. Christopher Michael Roman connects this moment to the continual theme of Wolverine stories in which he cares for a younger person, usually a young woman. While it might seem that Wolverine is learning to be a surrogate father, Roman claims that the kinship bonds are more complicated than a father-child relationship. In his relationship with Kitty Pryde, Roman argues that Wolverine actually teaches her to redefine herself without relying on a father figure, and that their bond is grounded in shared vulnerability. He also draws attention to Wolverine's role as a mentor to other characters like Colossus, Jubilee, Armor, and Quentin Quire.
== Clinical use == The most frequent use of aminoglycosides is empiric therapy for serious infections such as sepsis, complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial respiratory tract infections. Usually, once cultures of the causal organism are grown and their susceptibilities tested, aminoglycosides are discontinued in favor of less toxic antibiotics. The recent emergence of infections due to Gram-negative bacterial strains with advanced patterns of antimicrobial resistance has prompted physicians to reevaluate the use of these antibacterial agents. This revived interest in the use of aminoglycosides has brought back to light the debate on the two major issues related to these compounds, namely the spectrum of antimicrobial susceptibility and toxicity. Current evidence shows that aminoglycosides do retain activity against the majority of Gram-negative clinical bacterial isolates in many parts of the world. Still, the relatively frequent occurrence of nephrotoxicity and ototoxicity during aminoglycoside treatment makes physicians reluctant to use these compounds in everyday practice. Recent advances in the understanding of the effect of various dosage schedules of aminoglycosides on toxicity have provided a partial solution to this problem, although more research still needs to be done in order to overcome this problem entirely.
== Further reading == Abbott G. European and Muscovite: Ivan Kireevsky and the origins of Slavophilism (Cambridge University Press, 1972) Agnew H. Origins of the Czech National Renascence (University of Pittsburgh Press, 1993) Carole R. The Slovenes and Yugoslavism, 1890-1914 (Columbia University Press, 1977) Djokic D. (ed.) Yugoslavism. Histories of a Failed Idea, 1918-1992 (Hurst and Company, 2003) Gasor A., Karl L., Troebst S. (eds.) Post-Panslavismus. Slavizität, Slavische Idee und Antislavismus im 20. und 21. Jahrhundert (Wallstein Verlag, 2014) Geier, Wolfgang (2022). Panslawismus [Pan-Slavism]. Enzyklopädie des europäischen Ostens, vol. 20,4. Klagenfurt: Wieser, ISBN 978-3-99029-535-9. Golub I., Bracewell C. The Slavic Idea of Juraj Krizanic, Harvard Ukrainian Studies 3-4 (1986). Grigorieva, Anna A. (2010). "Pan-Slavism in Central and Southeastern Europe" (PDF). Journal of Siberian Federal University. Humanities & Social Sciences. 3 (1): 13–21. Retrieved 22 September 2018. Kohn, Hans. Nationalism: Its meaning and history (van Nostrand, 1955). Kohn, Hans (1961). "The Impact of Pan-Slavism on Central Europe". The Review of Politics. 23 (3): 323–333. doi:10.1017/s0034670500008767. JSTOR 1405438. S2CID 145066436. Kostya S. Pan-Slavism (Danubian Press, 1981) Osmańczyk, Edmund Jan (2003). "Pan-Slavism". Encyclopedia of the United Nations and International Agreements: N to S. Taylor & Francis. pp. 1762–. ISBN 9780415939232. Retrieved 22 September 2018. Petrovich B.M.
Sources: en.wikipedia.org
A myxoma (New Latin from Greek muxa 'mucus') is a myxoid tumor of primitive connective tissue. It is most commonly found in the heart (and is the most common primary tumor of the heart in adults) but can also occur in other locations.
The 1993 film Jurassic Park (based on the 1990 Michael Crichton novel of the same name) features dinosaurs that were genetically altered so that they could not produce the amino acid lysine. This was known as the "lysine contingency" and was supposed to prevent the cloned dinosaurs from surviving outside the park, forcing them to be dependent on lysine supplements provided by the park's veterinary staff. In reality, no animals are capable of producing lysine (it is an essential amino acid). Autotroph Bradytroph "Regulation of endosomal clathrin and retromer-mediated endosome to Golgi retrograde transport by the J-domain protein RME-8" - The EMBO Journal "Pleiotropic effects of purine auxotrophy inRhizobium meliloti on cell surface molecules" - Springerlink "Auxotrophy and Organic Compounds in the Nutrition of Marine Phytoplankton"
Cell division is essential for an organism to grow, but, when a cell divides, it must replicate the DNA in its genome so that the two daughter cells have the same genetic information as their parent. The double-stranded structure of DNA provides a simple mechanism for DNA replication. Here, the two strands are separated and then each strand's complementary DNA sequence is recreated by an enzyme called DNA polymerase. This enzyme makes the complementary strand by finding the correct base through complementary base pairing and bonding it onto the original strand. As DNA polymerases can only extend a DNA strand in a 5′ to 3′ direction, different mechanisms are used to copy the antiparallel strands of the double helix. In this way, the base on the old strand dictates which base appears on the new strand, and the cell ends up with a perfect copy of its DNA.
PC Zone gave a rating of four out of five to version 1.0, saying there are few maps but they are well designed and the weapon arsenal is comprehensive. They gave a same rating to version 1.3A and wrote: "It's not quite as involved or atmospheric as Counter-Strike, but it's more user-friendly [...]" They gave a rating of 90 out of 100 to version 1.7A and called it "one the of the top mods around". In 2007, PC Zone included the mod on their Classic: MOD column, writing: "The quality of its maps and weapons are what really sets Front Line Force apart from similar mods of the day." 4Players gave a rating of 88 out of 100 and called the mod a genuine alternative to players who want more than just team deathmatch gameplay. PCZeta said the mod combines the best of Counter-Strike and Team Fortress Classic and pushes the teamplay concept further. Xtreme PC noted all weapons as excellent and the map selection as magnificent. Konsolipelaaja noted Front Line Force as more polished and engaging than Counter-Strike. PC PowerPlay said the mod is more strategic than Counter-Strike. Micromanía said the graphics are quite good but the character animation leaves something to be desired. Level called the maps gorgeous and the attention to detail in them downright obsessive. Planet Half-Life wrote: "Front Line Force is the mod for you if you're looking for a tactical game without all the realism that's currently in vogue." PC Action called it a decent alternative to Counter-Strike with a small but dedicated fanbase.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.